Skip to main content

Table 3 Baseline E-RS scores, overall and by GOLD group

From: The effect of aclidinium bromide on daily respiratory symptoms of COPD, measured using the Evaluating Respiratory Symptoms in COPD (E-RS: COPD) diary: pooled analysis of two 6-month Phase III studies

  RS-Totala RS-Breathlessnessb RS-Cough & Sputumc RS-Chest Symptomsd
mean (SD) mean (SD) mean (SD) mean (SD)
All patients
 Placebo (n = 578) 12.4 (6.5) 6.3 (3.6) 3.4 (1.9) 2.7 (2.0)
 Aclidinium 400 μg BID (n = 583) 12.7 (6.8) 6.4 (3.7) 3.5 (1.9) 2.9 (2.1)
 Total (n = 1161) 12.6 (6.6) 6.3 (3.6) 3.4 (1.9) 2.8 (2.0)
GOLD Group A
 Placebo (n = 52) 4.6 (3.2) 2.0 (1.7) 1.6 (1.3) 0.9 (1.2)
 Aclidinium 400 μg BID (n = 42) 6.0 (5.2) 2.3 (2.7) 2.3 (1.8) 1.4 (1.7)
 Total (n = 94) 5.2 (4.3) 2.1 (2.2) 2.0 (1.6) 1.1 (1.5)
GOLD Group B
 Placebo (n = 270) 13.1 (5.9) 6.5 (3.2) 3.6 (1.8) 3.0 (1.8)
 Aclidinium 400 μg BID (n = 296) 13.1 (6.5) 6.4 (3.5) 3.6 (1.9) 3.1 (2.0)
 Total (n = 566) 13.1 (6.2) 6.4 (3.3) 3.6 (1.8) 3.1 (1.9)
GOLD Group C
 Placebo (n = 20) 6.5 (4.4) 3.0 (2.1) 2.0 (1.6) 1.5 (1.5)
 Aclidinium 400 μg BID (n = 22) 6.0 (3.4) 2.3 (1.7) 2.4 (1.5) 1.3 (1.2)
 Total (n = 42) 6.2 (3.9) 2.6 (1.9) 2.2 (1.6) 1.4 (1.4)
GOLD Group D
 Placebo (n = 236) 13.9 (6.4) 7.3 (3.5) 3.6 (1.8) 2.9 (2.0)
 Aclidinium 400 μg BID (n = 223) 14.2 (6.5) 7.5 (3.4) 3.6 (2.0) 3.2 (2.1)
 Total (n = 459) 14.0 (6.5) 7.4 (3.5) 3.6 (1.9) 3.0 (2.1)
  1. n = patients with available data
  2. aRS-Total score ranged from 0 to 40
  3. bRS-Breathlessness domain score ranged from 0 to 17
  4. cRS-Cough & Sputum domain score ranged from 0 to 11
  5. dRS-Chest Symptoms domain score ranged from 0 to 12
  6. Higher scores indicate more severe symptoms
  7. RS-Total and domain scores were higher in GOLD Groups B and D compared with Groups A and C (all p < 0.001; ANCOVA). RS-Total and RS-Breathlessness scores were higher in GOLD Group D compared with Group B (both p < 0.001; ANCOVA)
  8. ANCOVA, analysis of covariance; BID, twice daily; E-RS, Evaluating Respiratory Symptoms; GOLD, Global initiative for chronic Obstructive Lung Disease; SD, standard deviation